NGNE - CONSENSUS CO - Neurogene Inc.

The investment profile of Neurogene Inc. (NGNE) is burdened by a high probability of new drug trial failures and vector production costs, which makes the consensus valuation 79.02. This price action chart, serving as confirmation of the market valuation, visualizes these expectations. Neurogene Inc. (NGNE) creates unique gene expression regulation methods for the therapy of rare brain pathologies. Currently, the business relies exclusively on R&D, lacking any sources of stable income.

For Neurogene Inc., a leader in developing unique gene therapies without direct pricing competition, the consensus target price serves as an indicator of market recognition for its intellectual capital. This metric aggregates independent analyst calculations, measuring the gap between the current price and the asset's fair value, which allows investors to assess the stock's long-term growth potential based on fundamental expectations.